REG - ValiRx PLC - Inaphaea Commercial update

ValiRxAnnouncement

Tue 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251014:nRSN1829Da&default-theme=true

RNS Number : 1829D  ValiRx PLC  14 October 2025

 

ValiRx PLC

("ValiRx" or the "Company")

 

Inaphaea Commercial update

London, UK - ValiRx Plc (AIM: VAL), a life sciences company focusing on
early-stage cancer therapeutics and women's health, is pleased to provide the
following updates on its wholly owned subsidiary Inaphaea Limited
("Inaphaea").

Inaphaea is delighted to confirm the completion of the second phase of the
Amply Discovery Limited's ("Amply") service contract, announced on 19 November
2024 and receipt of a balancing payment of approximately £31,000.

 

Inaphaea is also pleased to announce that, following the award of a Knowledge
Transfer Voucher with The Open University announced on 7 August 2025, the
academic partner has been awarded a £250,000 UK Research and Innovation
("UKRI") grant to further develop its in-silico spheroid modelling platform.
Inaphaea, as the commercial partner, will supply its Patient Derived Cells
("PDC") for production of spheroids and share data generated on the PDCs
including drug response profiling. Inaphaea will also evaluate the in-silico,
predictive models as part of its commitment to New Advanced Methodologies
("NAMs") for drug development.

Inaphaea is receiving weekly updates and access to PDC samples under its
agreement with Nottingham Health Trust, announced on 18 September 2025, whilst
the first four ovarian PDCs from the Biobank have been successfully digitised
by its partner TwinEdge BioScience ("TwinEdge"). The digital avatars created
from the four PDCs exceeded all quality controls and TwinEdge will now move to
phase 2 of the agreement which involves creating digital avatars of the
remaining 63 ovarian PDC models with available RNA-sequence data.

 

ValiRx is also pleased to announce it has signed an agreement with Apis Assay
Technologies Ltd ("APIS") to evaluate APIS's HER2 targeting Clickmer - based
on APIS's novel modified aptamer technology. Initially for use on
characterising the expression of HER2 on Inaphaea's PDCs, the technology will
also be applied to CytoLytix's oncolytic peptide platform in order to
selectively target HER2 positive cancer cells, including breast and ovarian
cancer.

 

In addition to the commercial update, Dr Amelia Hatfield, recently promoted to
Lead Scientist - Translational Science and Academic Liaison at Inaphaea, has
been granted Visiting Lecturer status at Kings College London which will
facilitate the ongoing collaboration with CytoLytix. Dylon Jones, Inaphaea's
technician, has commenced a Level 6 Degree Apprenticeship in Applied
Biosciences (BSc Hons) through Middlesex University and delivered via Tiro
Training Ltd. ("Tiro"). Cathy Tralau-Stewart, Executive Director of the Milner
Institute and Non-Executive Director of ValiRx has been appointed as a
Research Professor (Therapeutics) at the University of Cambridge.

 

Mark Eccleston, CEO of ValiRx commented "We are very pleased to have
successfully completed the first three phases of the contract with Amply and
to have recognised the revenue as we continue to build the sales pipeline."

 

"Our partnership with The Open University is going from strength to strength
with the latest pump priming award being rapidly followed by a significant
grant award for our partner which will benefit Inaphaea through shared data
generation and publications using our PDCs. We strongly believe that more
realistic disease models provide better results and have been developing our
biobank to offer a range of services based on 2D and 3D culture models under
normoxia and hypoxia. These low passage, non-immortalised models, supported by
extensive RNA-sequence data, are closer to, and therefore more representative
of, the patient which should ultimately translate to improved understanding of
the candidate drugs and reduced failures in the clinic."

 

 "We're excited by the potential for these models to be digitised through
TwinEdge Bioscience and this collaboration has the potential to transform the
way we access indicative clinical performance rapidly and economically
alongside biomarker identification for patient selection for both our in house
and client programs. The relationship with TwinEdge continues to grow as we
expand the range of PDCs, adding to their selection of over 10,000 patient
avatars. The data generated from these models is helping build more
sophisticated patient avatars as the collaboration builds momentum."

 

"We are also really pleased to be working with APIS and to have access to
their proprietary aptamer-based Clickmer technology. This is another win-win
collaboration where we can help validate their HER2 targeting Clickmer whilst
generating data on our PDCs. Going forward we will explore a commercial
partnership to develop targeted CLX-001 derivatives."

"I'd also like to offer my congratulations to Amelia and Cathy for their
recent academic appointments and Dylan for starting his degree apprenticeship.
It is an important part of the upskilling of our technical team."

 

The information contained within this announcement is deemed by the Company to
constitute inside information as stipulated under the Market Abuse Regulations
(EU) No. 596/2014 as it forms part of UK Domestic Law by virtue of the
European Union (Withdrawal) Act 2018 ("UK MAR"). The Directors of the Company
take responsibility for this announcement.

*** ENDS ***

Engage with the ValiRx management team directly by asking questions, watching
video
summaries and seeing what other shareholders have to say. Navigate to
our Interactive Investor
hub here: https://valirx.com/s/cc8ef3

For more information, please contact:

 

 Investor questions on this announcement           https://valirx.com/link/yEMZvy

 We encourage all investors to share questions

 on this announcement via our investor hub
 ValiRx plc                                        Tel: +44 115 784 0026

                                                   www.valirx.com (http://www.valirx.com)

 Dr Mark Eccleston, CEO                            Mark.Eccleston@valirx.com

 Cairn Financial Advisers LLP (Nominated Adviser)  Tel: +44 (0) 20 7213 0880

 Liam Murray / Ludovico Lazzaretti

 Shard Capital Partners LLP (Sole Broker)          Tel: +44 (0) 20 7186 9000

 Damon Heath

 V Formation (Public Relations)                    +44 (0) 115 787 0206

                                                   www.vformation.biz (http://www.vformation.biz)

 Lucy Wharton - Senior PR Executive

 Sue Carr - Director                               lucy@vformation.biz

                                                   sue@vformation.biz

 

Subscribe to our news alert service: https://valirx.com/s/f298d1
(https://valirx.com/s/f298d1)

 

Notes for Editors

About ValiRx

ValiRx is a life science company focused on early-stage cancer therapeutics
and women's health, accelerating the translation of innovative science into
impactful medicines to improve patient lives.

ValiRx provides the scientific, financial, and commercial framework for
enabling rapid translation of innovative science into clinical development.

Using its extensive and proven experience in research and drug development,
the team at ValiRx selects and incubates promising novel drug candidates and
guides them through an optimised process of development, from pre-clinical
studies to clinic and investor-ready assets.

ValiRx connects diverse disciplines across scientific, technical, and
commercial domains, with the aim of achieving a more streamlined, less costly,
drug development process. The team works closely with carefully selected
collaborators and leverages the combined expertise required for science to
advance.

Lead candidates from ValiRx's portfolio are outlicensed or partnered with
investors through ValiRx subsidiary companies for further clinical development
and commercialisation.

ValiRx listed on the AIM Market of the London Stock Exchange in October 2006
and trades under the ticker symbol: VAL.

For further information, visit: www.valirx.com (http://www.valirx.com)

 

Caution regarding forward looking statements

Certain statements in this announcement, are, or may be deemed to be, forward
looking statements. Forward looking statements are identified by their use of
terms and phrases such as ''believe'', ''could'', "should" ''envisage'',
''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect",
''will'' or the negative of those, variations or comparable expressions,
including references to assumptions. These forward-looking statements are not
based on historical facts but rather on the Directors' current expectations
and assumptions regarding the Company's future growth, results of operations,
performance, future capital and other expenditures (including the amount,
nature and sources of funding thereof), competitive advantages, business
prospects and opportunities. Such forward looking statements reflect the
Directors' current beliefs and assumptions and are based on information
currently available to the Directors.

Such statements are based on current expectations and assumptions and are
subject to a number of risks and uncertainties that could cause actual events
or results to differ materially from any expected future events or results
expressed or implied in these forward-looking statements.  Persons receiving
and reading this announcement should not place undue reliance on
forward-looking statements. Unless otherwise required by applicable law,
regulation or accounting standard, the Company does not undertake to update or
revise any forward-looking statements, whether as a result of new information,
future developments or otherwise.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDBLBDGDUBDGUX



            Copyright 2019 Regulatory News Service, all rights reserved